Funder: National Institutes of Health

Due Dates: January 11, 2025 (Open date) | February 11, 2025 (New) | March 11, 2025 (Renewal/Resubmission/Revision) | May 11, 2025 (AIDS) | June 11, 2025 (New) | July 11, 2025 (Renewal/Resubmission/Revision) | September 11, 2025 (AIDS) | October 10, 2025 (New) | November 10, 2025 (Renewal/Resubmission/Revision) | January 11, 2026 (Current closing) | January 12, 2026 (Final/Expiration)

Funding Amounts: Budgets are not limited; project period up to 5 years (1 year R61, up to 4 years R33); actual funding based on project needs and NIH appropriations.

Summary: Supports investigator-initiated, single-site clinical trials relevant to NHLBI’s mission using a bi-phasic, milestone-driven R61/R33 mechanism.

Key Information: Only single-site trials (not multi-site); direct costs ≥$500K/year require NHLBI staff consultation before applying.